PIK3CA and non-small cell lung carcinoma: Buparlisib (Novartis) is a pan-PI3K inhibitor, which was assessed in a PIK3CA-activated [defined as PIK3CA mutation, PTEN mutation, or PTEN loss (less than 10% protein expression by IHC)] NSCLC population.